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Acute lymphoblastic leukemia (ALL) is characterized by an outgrowth of malignant lymphoblasts that occupy the bone marrow microenvironment where they reside with mesenchymal stromal cells (MSCs).
1 Leukemic cells are able to disrupt the healthy microenvironment and create a leukemic niche that shelters malignant cells from elimination through cytostatic treatment and immune responses.
2,3
Disrupting intercellular communication in this malignant microenvironment sensitizes leukemic cells to chemotherapeutic drugs. 4 Homing of ALL cells toward the bone marrow microenvironment is thought to be similar to that of hematopoietic stem cells (HSCs). 5 Human CD34 + progenitor cells, are attracted by stromal cell-derived factor 1 (SDF-1/CXCL12), a chemoattractant actively produced by MSCs in the bone marrow. 5, 6 CXCL12 binds to the CXCR4 receptor. Disturbance of the CXCR4/CXCL12 axis by treatment with cytokines and/or CXCR4 antagonists mobilizes HSCs to the peripheral blood 7 and shows promising pre-clinical results in acute myeloid leukemia patients. 8 Like HSCs, ALL cells have high CXCR4 surface expression and disruption of CXCR4/CXCL12 interaction reduces ALL engraftment in animal models. 9, 10 However, in mice suffering from ALL, CXCR4/CXCL12 inhibition as mono-treatment did not reduce the leukemic cell number in the bone marrow. 9, 11 In addition, CXCL12 expression was remarkably down-regulated in murine bone marrow regions of extensive ALL growth.
1 Likewise, CXCL12 levels in the bone marrow of patients diagnosed with BCP-ALL were lower compared to those in the same patients at the time of remission and healthy controls. 6 This suggests that ALL cells use additional mechanisms to retain a protective microenvironment.
In this study, we used an ex vivo co-culture model in which we cultured B-cell precursor ALL (BCP-ALL) cells with bone marrow-derived primary MSCs. Several studies show that ALL cells home toward the bone marrow microenvironment in a CXCR4/CXCL12-dependent manner. 1, 9, 10 We confirmed these findings in our model by assessing the migration of GFP-positive BCP-ALL cells (NALM6) toward MSCs using a transwell system. MSCs induced migration of BCP-ALL cells by 5-16-fold compared to medium controls (P<0.05) ( Figure 1A and Online Supplementary Figure S1A and B). The induction of migration was correlated with the level of CXCL12 produced by the primary MSCs ( Figure 1B) . Inhibition of the CXCR4/CXCL12 axis with AMD3100 significantly impaired migration of BCP-ALL cells toward MSCs (4.5-fold reduction; P<0.01) ( Figure  1C) .
Next, we hypothesized that BCP-ALL cells alter the chemoattractive properties of their microenvironment. To address this hypothesis, GFP-negative BCP-ALL cells (NALM6) were cultured with MSCs in the bottom compartment of a transwell system as a model of the leukemic niche. Migration of GFP-positive BCP-ALL cells (NALM6) from the upper to the bottom compartment was determined (Online Supplementary Figure S1A-C) . GFP-positive BCP-ALL cells migrated significantly more toward ALL-MSC co-cultures than toward MSCs in mono-culture (blue bars vs. gray bars; P<0.01) ( Figure 1D and Online Supplementary Figure S1D and E). The leukemic niche induced migration of BCP-ALL cells by 2.2-fold (P<0.001) ( Figure 1E) . Surprisingly, CXCR4 inhibition by AMD3100 did not affect the preferential migration of BCP-ALL cells towards the leukemic niche (2.2-fold vs. 2.5-fold; P=0.52) ( Figure 1E and Online Supplementary Figure S1F) . In addition, we compared CXCL12 levels in the supernatant of mono-and co-cultures of primary BCP-ALL cells derived from 9 different BCP-ALL cases and 4 primary MSCs. CXCL12 levels were high in mono-cultures of MSCs, and below detection level in mono-cultures of primary BCP-ALL cells (Online Supplementary Figure S2A and B). Co-culture of primary BCP-ALL cells and MSCs did not increase CXCL12 levels compared to the combined levels produced in both mono-cultures ( Figure 1F ). These results suggest that BCP-ALL cells create a leukemic niche that attracts leukemic cells in a CXCR4/CXCL12-independent manner.
Next, we assessed the migration of healthy CD34 + hematopoietic progenitor cells (HPCs) toward primary MSCs cultured with or without BCP-ALL cells. As expected, CD34 + HPCs migrated more abundantly toward MSCs than to control medium without MSCs (1.8-fold; P<0.05) ( Figure 1G ). However, migration of CD34 + HPCs toward ALL-MSC co-cultures was significantly reduced compared to migration toward MSCs in mono-cultures (20% reduction; P<0.05) ( Figure 1G ). In addition, we assessed the migratory behavior of healthy MSCs toward ALL-MSC cocultures. We performed a transwell migration assay in which primary MSCs were allowed to migrate toward BCP-ALL cells or other MSCs in the bottom compartment. We observed that MSC migration was induced toward other MSCs compared to control medium (P<0.05) ( Figure 1H ). Strikingly, MSCs also actively migrated to BCP-ALL cells illustrating that BCP-ALL cells are able to recruit MSCs (P<0.001) (Figure1H and Online Supplementary Figure  S3A ). However, MSC migration was significantly inhibited toward the leukemic niche (ALL-MSC co-cultures) compared to a bottom compartment containing only BCP-ALL cells (2-3-fold reduction; P<0.001) ( Figure 1I and Online Supplementary Figure S3B and C). Interestingly, increasing the amount of ALL cells (up to 16-fold) in ALL-MSC co-cultures did not re-induce MSC migration ( Figure 1I ). These results show that ALL-MSC co-cultures efficiently attract leukemic cells, but reduce migration of healthy CD34 + HPCs and primary MSCs, suggesting that ALL-MSC co-cultures produce chemokines that specifically attract BCP-ALL cells.
To address which cytokines/chemokines may be altered in the leukemic niche, we quantified the levels of 64 cytokines known to be important in immunology/hematology in the supernatant of ex vivo co-cultures of patientderived BCP-ALL cells (n=10, representing major BCP-ALL subgroups) and MSCs (n=4) (Online Supplementary Table  S1 Table S2 and Online Supplementary Figure S4A and B). These unique cytokine/chemokine profiles suggest the need for patient-specific approaches to disrupt the leukemic niche. However, we also found recurrently induced signaling pathways. All ALL-MSC co-cultures showed increased levels of CCL2/MCP-1 and/or CCL22/MDC (Figure 2A) , both ligands for the CCR4 receptor. This chemokine receptor is implicated in T-cell leukemia and lymphoma, but has not yet been implicated as an important factor in BCP-ALL. 12 In addition, analysis of previously published microarray-based gene expression data showed that CCR4 expression levels in pediatric ALL haematologica 2017; 102:e389 Figure S4C) .
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In addition, we observed recurrent induction of CXCL8/IL-8 and CXCL1/GRO secretion, ligands of the CXCR1 and CXCR2 receptor. CXCR1/2 ligands were induced by BCP-ALL cells from 6 out of 10 patients ( Figure 2C ). In contrast to CCR4 expression, CXCR1 and CXCR2 expression levels were lower in pediatric ALL compared to healthy hematopoietic cells (Online Supplementary Figure S3C) .
We validated the cytokine/chemokine patterns identified in our co-culture model using serum derived from bone marrow aspirates from 10 ALL patients at diagnosis. We compared the cytokine/chemokine patterns in these samples with serum obtained from bone marrow aspirates of the same patients taken at the end of induction chemotherhaematologica 2017; 102:e390
(E) Graph showing that the leukemic niche affects the migration of BCP-ALL cells independent of CXCR4/CXCL12 signaling. Migration of NALM6 cells toward NALM6-MSC co-cultures (leukemic niche, blue bars) is compared to migration toward MSC mono-cultures (normal niche, gray bars) in absence or presence of AMD3100 (10 µM) after 48 h using a 3.0 µm transwell system (n=4; one-tailed t-test, paired). For this experiment, we combined the data of four distinct primary MSCs (MSC#1-4). Data are shown as fold-induction compared to migration towards MSC mono-culture. (F) Plots show the secreted levels of CXCL12 by primary BCP-ALL cells and MSCs in mono-culture (circles represent the sum of cytokine secretion in mono-culture of BCP-ALL and mono-culture of MSC) compared to ALL-MSC co-culture (squares). Data were determined using a multiplexed fluorescent bead-based immunoassay. Boxes represent p25-p75 intervals. 
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apy. At this stage of treatment, the patients were in remission. Furthermore, we used bone marrow aspirates of 7 healthy controls to analyze cytokine/chemokine patterns of the healthy niche. Levels of the CCR4 ligand CCL2/MCP-1 were significantly higher in the bone marrow of untreated, newly diagnosed BCP-ALL patients compared to healthy controls (2.0-fold increase; P<0.01) ( Figure 2B ). Interestingly, after induction therapy, the CCL2/MCP-1 levels in the bone marrow of ALL patients decreased to levels observed in healthy controls (2.2-fold decrease; P<0.01) ( Figure 2B ). This suggests that the induced CCL2/MCP-1 levels at diagnosis are causally linked to the presence of leukemic cells. CCL22/MDC levels were similar between BCP-ALL patients and healthy controls ( Figure 2B ). Like CCL2/MCP-1, CXCL1/GRO levels were also increased in the bone marrow of BCP-ALL patients (2.3-fold increase; P<0.05) ( Figure 2D ) and CXCL8/IL8 levels showed a trend towards upregulation (2.5-fold; P=0.052) ( Figure 2D ). Similar to CCL2/MCP-1 levels, the secreted levels of these CXCR1/2 ligands were significantly reduced after induction chemotherapy (2.3-fold and 3.1-fold, respectively; P<0.05) ( Figure 2D ). These data implicate that CCR4 and CXCR1/2 signaling are important in the bone marrow of BCP-ALL patients and suggest that CCR4 inhibition (e.g. by mogamulizumab1) 13 or CXCR1/2 inhibition might be an alternative or additional way to disrupt the BCP-ALL niche.
In conclusion, our data indicate that the BCP-ALL niche is highly potent in attracting BCP-ALL cells and repelling the influx of healthy hematopoietic cells and MSCs in a CXCL12-independent manner. Instead, we show the recurrent induction of CCR4 and CXCR1/2 ligands by BCP-ALL cells in the leukemic niche (Figure 3 ). Our data suggest CCR4 and CXCR1/2 to be valuable future therapeutic targets to interfere with the leukemic niche in ALL. 
